Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.

@article{Griggs2016PioglitazoneIT,
  title={Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.},
  author={Ryan B Griggs and Ren{\'e}e R. Donahue and Braxton G Adkins and Katie L. Anderson and Olivier Thibault and Bradley Kenneth Taylor},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2016},
  volume={17 3},
  pages={
          359-73
        }
}
UNLABELLED Thiazolidinedione drugs (TZDs) such as pioglitazone are approved by the U.S. Food and Drug Administration for the treatment of insulin resistance in type 2 diabetes. However, whether TZDs reduce painful diabetic neuropathy (PDN) remains unknown. Therefore, we tested the hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker Diabetic Fatty (ZDF(fa/fa) [ZDF]) rats. Compared with Zucker Lean (ZL(fa/+)) controls, ZDF rats developed: (1) increased blood glucose… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 114 REFERENCES

Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K

CA Abbott, RA Malik, ER van Ross, J Kulkarni, AJ. Boulton
  • Diabetes Care
  • 2011
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Electrophysiological characterization of spinal neurons in different models of diabetes type 1 and type 2- induced neuropathy in rats

N Schuelert, N Gorodetskaya, S Just, H Doods, L. Corradini
  • Neuroscience. 291:146-154,
  • 2015

Similar Papers

Loading similar papers…